株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

関節リウマチ治療薬の世界市場:2016〜2020年

Global Rheumatoid Arthritis Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 353175
出版日 ページ情報 英文 126 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
関節リウマチ治療薬の世界市場:2016〜2020年 Global Rheumatoid Arthritis Drugs Market 2016-2020
出版日: 2016年02月17日 ページ情報: 英文 126 Pages
概要

関節リウマチは30〜60歳にみられる慢性的な炎症性自己免疫疾患です。遺伝や環境要素が発症に寄与していると考えられています。DMARD、NSAID、コルチコステロイド、鎮静剤などが関節リウマチ患者の治療として開発され、投与されています。世界の関節リウマチ治療薬市場は、2016〜2020年にかけCAGR3.43%で拡大すると予測されています。

当レポートでは、世界の関節リウマチ治療薬市場の現状と今後の成長見通し、地域別動向とともに、市場の動向と課題、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

  • 市場ハイライト

第5章 疾患の概要

  • 関節リウマチの理解
  • 病因と病態生理学
  • 徴候と症状
  • 診断
  • 疾患の管理
  • 経済的負担
  • 疫学

第6章 関節リウマチにおける生物製剤の影響

第7章 パイプラインポートフォリオ

  • パイプライン候補が標的とする新規の機序
  • 治験

第8章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 薬剤クラス別市場セグメンテーション

  • DMARD
  • NSAID
  • コルチコステロイド
  • 鎮静剤
  • その他
  • 世界のDMARD市場
  • 世界のNSAID市場
  • 世界のコルチコステロイド市場
  • 世界の鎮静剤市場

第10章 作用機序別市場セグメンテーション

  • TNF阻害剤
  • IL-1阻害剤
  • JAK阻害剤
  • 選択的副刺激調整剤

第11章 分子タイプ別市場セグメンテーション

  • 生物製剤
  • 小分子

第12章 投与ルート別市場セグメンテーション

  • 経口
  • 非経口
  • 局所

第13章 剤形別市場セグメンテーション

  • 固体
  • 液体
  • 半固体

第14章 地域別セグメンテーション

  • 南北アメリカ
  • 米国
  • 欧州・中東・アフリカ
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • フランス
  • アジア太平洋地域
  • 日本
  • オーストラリア
  • インド
  • 中国

第15章 主要国

第16章 市場促進因子

第17章 促進因子の影響

第18章 市場の課題

第19章 促進因子および課題の影響

第20章 市場動向

第21章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析
  • AbbVie
  • Amgen
  • BMS
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Pfizer
  • その他の注目すべきベンダー

第22章 付録

第23章 Technavioについて

図表

目次
Product Code: IRTNTR8751

About Rheumatoid Arthritis Drugs

RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.

Technavio's analysts forecast the global RA drugs market to grow at a CAGR of 3.43% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global RA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat the disease.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Rheumatoid Arthritis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb (BMS)
  • Johnson & Johnson
  • Pfizer
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • Ablynx
  • Alder BioPharmaceuticals
  • Antares Medical Services
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • ChemoCentryx
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Incyte
  • KaloBios Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Merck
  • Morphotek
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Takeda Pharmaceuticals
  • UCB
  • Vertex Pharmaceuticals

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Increasing costs of biologicals
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding RA
  • Etiology and pathophysiology
  • Signs and symptoms
  • Diagnosis
  • Disease management
  • Economic burden of RA
  • Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio

  • Novel mechanisms targeted by pipeline candidates
  • Clinical trials for RA

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by drug class

  • DMARDs
  • NSAIDs
  • Corticosteroids
  • Analgesics
  • Others
  • Global DMARDs market
  • Global NSAIDs market
  • Global corticosteroids market
  • Global analgesics market

PART 10: Market segmentation by MOA

  • TNF inhibitors
  • IL-1 blockers
  • JAK inhibitors
  • Selective costimulation modulators

PART 11: Market segmentation by type of molecule

  • Biologics
  • Small molecules

PART 12: Market segmentation by ROA

  • Oral
  • Parenteral
  • Topical

PART 13: Market segmentation by dosage form

  • Solid
  • Liquid
  • Semi-solid

PART 14: Geographical segmentation

  • RA drugs market in Americas
  • RA drugs market in US
  • RA drugs market in EMEA
  • RA drugs market in Germany
  • RA drugs market in UK
  • RA drugs market in Spain
  • RA drugs market in Italy
  • RA drugs market in France
  • Rheumatoid arthritis drugs market in APAC
  • RA drugs market in Japan
  • RA drugs market in Australia
  • RA drugs market in India
  • RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers

  • Growing older population
  • Market dominance of biologics
  • Promising drug pipeline
  • Changing lifestyle patterns
  • Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges

  • Increasing costs of biologicals
  • Loss of patent exclusivity of branded therapies
  • Use of complementary and alternative medicines (CAMs)
  • Adverse effects of drugs
  • Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends

  • Emergence of biosimilars
  • Patient assistance programs
  • Popularity of off-label and traditional treatment options
  • Strategic alliances
  • Increase in public awareness

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AbbVie
  • Amgen
  • BMS
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Pfizer
  • Other prominent vendors

PART 22: Appendix4

  • List of abbreviations4

PART 23: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for RA drugs
  • Exhibit 03: Classification of RA based on disease severity
  • Exhibit 04: Classification of RA based on disease severity 2016
  • Exhibit 05: Etiology and pathophysiology of RA
  • Exhibit 06: Signs and symptoms of RA
  • Exhibit 07: Diagnostic tests for RA
  • Exhibit 08: Treatment options for RA
  • Exhibit 09: Non-pharmacological therapies used for RA
  • Exhibit 10: Pharmacotherapy therapy for RA
  • Exhibit 11: Drugs used to treat RA
  • Exhibit 12: Classification of surgical treatment for RA
  • Exhibit 13: Percentage share of treatment of RA 2016
  • Exhibit 14: Historical milestones in treatment of RA
  • Exhibit 15: Treatment algorithm for RA
  • Exhibit 16: Economic burden of RA
  • Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
  • Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
  • Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
  • Exhibit 20: New cases of RA in UK per year 2016
  • Exhibit 21: Existing cases of RA in UK
  • Exhibit 22: Impact of biologics on various sectors
  • Exhibit 23: Pipeline molecules for RA
  • Exhibit 24: Novel targets of pipeline candidates
  • Exhibit 25: Candidates under development: Baricitinib
  • Exhibit 26: Candidates under development: Decernotinib
  • Exhibit 27: Candidates under development: CCX354
  • Exhibit 28: Candidates under development: Sirukumab
  • Exhibit 29: Candidates under development: Infliximab biosimilar
  • Exhibit 30: Candidates under development: Secukinumab
  • Exhibit 31: Candidates under development: Bimekizumab
  • Exhibit 32: Clinical trials of RA drugs by phase 2016
  • Exhibit 33: Clinical trials of RA drugs by status 2016
  • Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
  • Exhibit 35: Opportunities in RA drugs industry
  • Exhibit 36: Five forces analysis
  • Exhibit 37: Global RA drugs market segmentation by drug class
  • Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
  • Exhibit 39: NSAIDs used to treat RA
  • Exhibit 40: Market share of global RA drugs market by drug class 2015
  • Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
  • Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
  • Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
  • Exhibit 44: Global analgesics market 2015-2020 ($ billions)
  • Exhibit 45: Market segmentation of global RA drugs market by MOA
  • Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
  • Exhibit 47: Global RA drugs market share by MOA 2015
  • Exhibit 48: Global RA drugs market segmentation by type of molecule
  • Exhibit 49: Global RA drugs market share by type of molecules 2015
  • Exhibit 50: Global RA drugs market segmentation by ROA
  • Exhibit 51: Global RA drugs market segmentation by ROA 2015
  • Exhibit 52: Global RA drugs market segmentation by dosage form
  • Exhibit 53: Global RA drugs market segmentation by dosage form 2015
  • Exhibit 54: Global RA drugs by geography 2015
  • Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
  • Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 58: RA drugs market in Americas by country 2015
  • Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
  • Exhibit 60: RA drugs sales in US by drug class 2015
  • Exhibit 61: Drivers and challenges of RA drugs market in US
  • Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 63: RA drugs market in EMEA by country 2015
  • Exhibit 64: RA sales in EMEA by drug class 2015
  • Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
  • Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
  • Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
  • Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
  • Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
  • Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 71: RA drugs market in APAC by country 2015
  • Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
  • Exhibit 73: RA drugs sales in Japan by drug class 2015
  • Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
  • Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
  • Exhibit 76: RA drugs sales in Australia by drug class 2015
  • Exhibit 77: Drivers and challenges in RA drugs market in Australia
  • Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
  • Exhibit 79: RA sales in India by drug class 2015
  • Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
  • Exhibit 81: RA drugs sales in China by drug class 2015
  • Exhibit 82: Key leading countries
  • Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
  • Exhibit 84: FDA approval of biologicals
  • Exhibit 85: List of pipeline molecules
  • Exhibit 86: Lifestyle factors - Risk of rheumatoid arthritis
  • Exhibit 87: Impact of drivers
  • Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
  • Exhibit 89: Approval and patent expiries of top selling biologics
  • Exhibit 90: CAM therapies for RA
  • Exhibit 91: Usage of CAM in US
  • Exhibit 92: Side effects associated with RA
  • Exhibit 93: Impact of drivers and challenges
  • Exhibit 94: Patient assistance programs offered by companies
  • Exhibit 95: Revenue share of RA drugs by vendors 2015
  • Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
  • Exhibit 97: Competitive assessment of top RA drugs
  • Exhibit 98: Revenue share of RA drugs 2015
  • Exhibit 99: AbbVie: Product segmentation by revenue 2014
  • Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
  • Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
  • Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
  • Exhibit 103: Sales of Humira in major markets
  • Exhibit 104: AbbVie: SWOT analysis
  • Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
  • Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
  • Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
  • Exhibit 108: Amgen: SWOT analysis
  • Exhibit 109: BMS: Segmentation by revenue 20141
  • Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
  • Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
  • Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
  • Exhibit 113: Orencia sales for RA in major markets 2014
  • Exhibit 114: BMS: SWOT analysis
  • Exhibit 115: RA products by revenue 2014
  • Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
  • Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
  • Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
  • Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
  • Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
  • Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
  • Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
  • Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
  • Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
  • Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
  • Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
  • Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
  • Exhibit 128: Johnson & Johnson: SWOT analysis
  • Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
  • Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
  • Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
  • Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
  • Exhibit 133: Pfizer: SWOT analysis
Back to Top